Professor Syed Hussain

MBBS, MSc, MD, FRCP

Clinical Medicine, School of Medicine and Population Health

Professor and Consultant in Medical Oncology

Professor Syed Hussain
Professor Syed Hussain
Profile picture of Professor Syed Hussain
syed.hussain@sheffield.ac.uk
+44 114 215 9682

Full contact details

Professor Syed Hussain
Clinical Medicine, School of Medicine and Population Health
Room 228, 2nd Floor, Broomcross Building
Weston Park Hospital
Whitham Road
Sheffield
S10 2SJ
Profile

For enquiries, please contact - iicd-om-operational@sheffield.ac.uk

Professor Hussain graduated from Dow Medical College Karachi in 1994. He completed his general medical professional training in UK. He did his Doctorate in Oncology from University of Birmingham. He completed his medical oncology training in Birmingham, United Kingdom and received his certification and specialist registration in medical oncology.

Professor Hussain is Professor and Honorary Consultant in Medical Oncology at the University of Sheffield and Sheffield Teaching Hospitals NHS Trust. His major areas of interest are management of urological cancers, clinical trials, early drug development and translational medicine. He has set up several clinical trials from early phase to late phase studies during his career. His work on organ preservation in bladder cancer moved all the way from an early phase I study (Hussain et al Annals of Oncology 2001) to phase II efficacy study (Hussain et al BJC 2004) that led to a Cancer Research UK funded study BC2001 trial that was reported in New England Journal of Medicine (James, Hussain, Hall et al April 2012). This study has now changed the standard of care for patients with muscle invasive bladder cancer opting for organ preservation treatment globally. He has tailored split dose cisplatin regimen that has led to expand the spectrum of patients receiving cisplatin-based chemotherapy in bladder cancer (Hussain et al BJC 2004). He is a principal investigator of several studies in urological cancers. He was chief investigator of a national randomised placebo-controlled phase II neo-adjuvant study (NEOBLADE) in muscle invasive bladder cancer. He has served as a chief investigator of various early phase clinical trials, and translational studies. He is a chief investigator of a first in human window of opportunity study (INVEST) investigating the role of intravesical/intratumoral atezolizumab in patients with bladder cancer undergoing curative cystectomy. This is sponsored by STH and funded by Roche. He is also chief investigator of an international window of opportunity trial SOGUG NEOWIN investigating the role of erdafitinib and cetrelimab in FGF mutant bladder cancer patients undergoing curative cystectomy. This is jointly led by Hussain (UK), with Andrea Necchi (Italy), Yohann Loriot (France) and Guillermo Velasco (Spain) as other co-chief investigators. This study is funded by Janssen. He has authored over 125 peer-reviewed publications including 4 book chapters in textbooks of oncology. His Google scholar H-index is 40 with over 9800 citations (April 2023). He has published in high impact journals including New England Journal of Medicine, Lancet, Lancet Oncology, JAMA, JAMA Oncology, Journal of Clinical Oncology, European Urology, Annals of Oncology, Nature Communications, Clinical Cancer Research, British Journal of Cancer. He has been an invited speaker to number of national and international meetings and have delivered over 110 invited lectures. He has secured funding from cancer charities, national funding bodies and industries of over £15 million.

Professor Hussain was the member of NCRI Bladder and Renal group and Chair of the NCRI- Advanced Bladder Cancer sub-group in his national role. Professor Hussain was the expert witness to NICE on successful technology appraisals of Atezolizumab (2017), Avelumab (2021) and Nivolumab in Bladder cancer (2022).

Research interests

My major areas of interest are management of urological cancers, clinical trials, early drug development and translational medicine. I have set up a large number of clinical trials from early phase to late phase studies during my career.

My work on organ preservation in bladder cancer moved all the way from an early phase I study (Hussain et al Annals of Oncology 2001), to phase II efficacy study (Hussain et al BJC 2004) that led to a Cancer Research UK funded study BC2001 trial that was reported in New England Journal of Medicine (James, Hussain, Hall et al April 2012).

This study has now changed the standard of care for patients with muscle invasive bladder cancer opting for organ preservation treatment. I am principal investigator of a number of studies in urological cancers.

I am chief investigator of a national randomised placebo-controlled phase II neo-adjuvant study in muscle invasive bladder cancer and have served as chief investigator of various early phase trials, and translational studies.

I have authored over 90 peer-reviewed publications including 4 book chapters in textbooks of oncology and been an invited speaker to a number of national and international meetings. I have secured funding of over 10 million pounds from funding bodies.


Current Projects

  • Setting up of clinical trials in bladder cancers.
  • Early phase studies in bladder cancer.
  • Development of panel of Biomarkers in bladder cancer.
  • Translational research linked to bladder cancer clinical trials.
Publications

Show: Featured publications All publications

This person does not have any publications available.

All publications

Journal articles

Chapters

  • Hussain S & James ND (2013) A multidisciplinary approach in muscle-invasive disease In Hussain S (Ed.), American Society Clinical Oncology Education Book RIS download Bibtex download
  • Hussain S & Palmer DH (2013) Systematic chemotherapy for liver tumours In Fong , Poon , Tang , Dupuy & Berlin (Ed.), Hepatobiliary Cancer RIS download Bibtex download
  • Hussain S, James ND, Bryan R, Patel P & Viney R (2012) Bladder cancer, in Perez and Brady's Principles and Practice of Radiation Oncology In Halperin EC, Wazer DE, Perez CA & Brady LW (Ed.), Percy and Brady textbook of radiation oncology RIS download Bibtex download
  • Hussain S, Zarkar A & James N (2008) Concomitant chemo-radiotherapy principles and management In Price (Ed.), Treatment of Cancer RIS download Bibtex download
  • HUSSAIN SA, ZARKAR A & JAMES ND () Concomitant chemo-radiotherapy principles and management Syed A Hussain, Anjali Zarkar, Nicholas D James, Treatment of Cancer (pp. 1308-1317). Taylor & Francis RIS download Bibtex download

Conference proceedings papers

  • Ikram W, Naqvi SAA, Raina A, Fatima E, Siddiqi R, Islam M, Asghar N, Khakwani KZR, Khan AM, Hussain SA , Bryce AH et al (2022) Quantifying the absolute benefit of neoadjuvant chemotherapy followed by definitive therapy in patients with muscle-invasive bladder cancer: A systematic review and meta-analysis.. JOURNAL OF CLINICAL ONCOLOGY, Vol. 40(16) RIS download Bibtex download
  • Riaz IB, Naqvi SAA, He H, Asghar N, Siddiqi R, Khakwani KZR, Liu H, Hussain SA, Singh P, Murad M & Bryce AH (2022) Mixed treatment comparisons evaluating contemporary therapies in metastatic castration sensitive prostate cancer (mCSPC): A living systematic review. ANNALS OF ONCOLOGY, Vol. 33(7) (pp S1193-S1193) RIS download Bibtex download
  • Jones RJ, Hussain SA, Birtle AJ, Song YP, Enting D, Faust G, Hilman S, Jagdev S, McGovern UB, Parikh O , Lewis A et al (2022) A randomised, double blind, phase II clinical trial of maintenance cabozantinib following chemotherapy for metastatic urothelial carcinoma (mUC): Final analysis of the ATLANTIS cabozantinib comparison.. JOURNAL OF CLINICAL ONCOLOGY, Vol. 40(17) RIS download Bibtex download
  • Hussain SA, Lester JF, Jackson R, Gornall M, Elliott A, Crabb SJ, Huddart RA, Vasudev N, Birtle AJ, Worlding J , James ND et al (2020) Phase II randomized placebo-controlled neoadjuvant trial of nintedanib or placebo with gemcitabine and cisplatin in locally advanced muscle invasive bladder cancer (NEO-BLADE). JOURNAL OF CLINICAL ONCOLOGY, Vol. 38(6) RIS download Bibtex download
  • Andrews E, Curran C, Grivas P, Diamantopoulos LN, Drakaki A, Jain RK, Tandon A, Agarwal N, Tripathi A, Santos VS , Hussain SA et al (2020) Outcomes of advanced plasmacytoid urothelial carcinoma receiving systemic therapy. JOURNAL OF CLINICAL ONCOLOGY, Vol. 38(6) RIS download Bibtex download
  • James ND, Pirrie S, Liu W, Ford D, Zarkar A, Southgate E, Desai A & Hussain SA (2020) A phase I/II feasibility study of cetuximab with 5FU and mitomycin C or cisplatin with concurrent radiotherapy in muscle invasive bladder cancer. JOURNAL OF CLINICAL ONCOLOGY, Vol. 38(6) RIS download Bibtex download
  • Hussain SA (2019) Changing Landscape in the Management of Advanced Bladder Cancer. JOURNAL OF PATHOLOGY, Vol. 249 (pp S10-S10) RIS download Bibtex download
  • Porta N, Song YP, Hall E, Choudhury A, Owen R, Lewis R, Hussain S, James ND, Huddart RA & Hoskin P (2019) Hypo-Fractionation in Muscle-Invasive Bladder Cancer: An Individual Patient Data (IPD) Meta-Analysis of the BC2001 and BCON Trials. International Journal of Radiation Oncology*Biology*Physics, Vol. 105(1) (pp S138-S138) RIS download Bibtex download
  • Powles T, Wheater MJ, Din O, Geldart TR, Boleti E, Stockdale A, Sundar S, Robinson A, Ahmed I, Sarker S-J , Hussain SA et al (2015) A randomized phase II study of AZ2014 versus everolimus in patients with VEGF refractory metastatic clear cell renal cancer (mRCC).. Journal of Clinical Oncology, Vol. 33(7_suppl) (pp 409-409) RIS download Bibtex download
  • James ND, Pirrie S, Barton D, Brown JE, Billingham L, Collins SI, Daunton A, Birtle AJ, Chakraborti PR, Ford D , Hussain SA et al (2013) Clinical outcomes in patients with castrate-refractory prostate cancer (CRPC) metastatic to bone randomized in the factorial TRAPEZE trial to docetaxel (D) with strontium-89 (Sr89), zoledronic acid (ZA), neither, or both (ISRCTN 12808747).. JOURNAL OF CLINICAL ONCOLOGY, Vol. 31(18) RIS download Bibtex download
  • James ND, Pirrie S, Barton D, Brown JE, Billingham L, Collins SI, Daunton A, Birtle AJ, Chakraborti PR, Ford D , Hussain SA et al (2013) Clinical outcomes in patients with castrate-refractory prostate cancer (CRPC) metastatic to bone randomized in the factorial trapeze trial to docetaxel (D) with strontium-89 (Sr89), zoledronic acid (ZA), neither, or both (ISRCTN 12808747).. JOURNAL OF CLINICAL ONCOLOGY, Vol. 31(15) RIS download Bibtex download

Posters

  • Khetrapal P, Catto J, Ambler G, Ricciardi F, Khan S, Feber A, Dixon S, Williams N, Ahmed I, Charlesworth P , Cumberbatch M et al (2022) PD42-02 RESULTS OF THE INTRACORPOREAL ROBOTIC VS OPEN CYSTECTOMY (IROC) MULTI-CENTRE RANDOMISED TRIAL. RIS download Bibtex download

Preprints

Teaching interests

I regularly taught pharmacology to both undergraduate and postgraduate students in my previous roles and supervised both MSc and PhD students in both their projects and research.

Professional activities and memberships
  • Association of Cancer Physicians (ACP)
  • European Society of Medical Oncology (ESMO)
  • American Society of Clinical Oncology (ASCO)
  • NCRI Blader & Renal Clinical studies group
  • British Medical Association
  • Chair of the NCRI Advanced Bladder Cancer – subgroup